Krka d. d (KRK) - Total Liabilities

Latest as of September 2025: zł662.58 Million PLN ≈ $182.35 Million USD

Based on the latest financial reports, Krka d. d (KRK) has total liabilities worth zł662.58 Million PLN (≈ $182.35 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Krka d. d generate cash to assess how effectively this company generates cash.

Krka d. d - Total Liabilities Trend (2010–2024)

This chart illustrates how Krka d. d's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Krka d. d to evaluate the company's liquid asset resilience ratio.

Krka d. d Competitors by Total Liabilities

The table below lists competitors of Krka d. d ranked by their total liabilities.

Company Country Total Liabilities
Sartorius Aktiengesellschaft
XETRA:SRT3
Germany €5.80 Billion
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
USA $4.53 Billion
Campbell’s Co
NYSE:CPB
USA $10.99 Billion
Zhejiang Jingsheng Mech Electric
SHE:300316
China CN¥9.51 Billion
Oracle Financial Services Software Limited
NSE:OFSS
India Rs19.38 Billion
Baiyin Nonferrous Group Co Ltd
SHG:601212
China CN¥35.05 Billion
Zions Bancorporation
NASDAQ:ZION
USA $81.67 Billion

Liability Composition Analysis (2010–2024)

This chart breaks down Krka d. d's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Krka d. d worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.91 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.29 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.22 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Krka d. d's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Krka d. d (2010–2024)

The table below shows the annual total liabilities of Krka d. d from 2010 to 2024.

Year Total Liabilities Change
2024-12-31 zł611.24 Million
≈ $168.22 Million
+4.93%
2023-12-31 zł582.52 Million
≈ $160.32 Million
+6.11%
2022-12-31 zł548.99 Million
≈ $151.09 Million
-11.25%
2021-12-31 zł618.60 Million
≈ $170.25 Million
+27.88%
2020-12-31 zł483.73 Million
≈ $133.13 Million
-6.45%
2019-12-31 zł517.10 Million
≈ $142.31 Million
+16.26%
2018-12-31 zł444.80 Million
≈ $122.42 Million
+3.10%
2017-12-31 zł431.43 Million
≈ $118.74 Million
-7.63%
2016-12-31 zł467.07 Million
≈ $128.55 Million
+15.84%
2015-12-31 zł403.22 Million
≈ $110.97 Million
-9.15%
2014-12-31 zł443.85 Million
≈ $122.15 Million
+3.88%
2013-12-31 zł427.27 Million
≈ $117.59 Million
+10.63%
2012-12-31 zł386.23 Million
≈ $106.30 Million
-2.04%
2011-12-31 zł394.27 Million
≈ $108.51 Million
-9.34%
2010-12-31 zł434.88 Million
≈ $119.68 Million
--

About Krka d. d

WAR:KRK Poland Drug Manufacturers - Specialty & Generic
Market Cap
$8.81 Billion
zł32.01 Billion PLN
Market Cap Rank
#2478 Global
#10 in Poland
Share Price
zł1048.00
Change (1 day)
-0.19%
52-Week Range
zł758.00 - zł1060.00
All Time High
zł1060.00
About

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company's prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolis… Read more